Topic Hub
10 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 10 of 10 clinical reviews.
Copper tripeptide GHK-Cu is being explored off-label for cognitive support. Learn what the preclinical evidence shows, how clinicians monitor patients, and what labs to track.
Read clinical reviewIs copper tripeptide GHK-Cu effective for cognitive enhancement? We review the preclinical evidence, off-label status, safety concerns, and what clinicians actually know about GHK-Cu and brain health.
Read clinical reviewAn evidence-based review of copper tripeptide GHK-Cu for cognitive function. Covers preclinical gene-expression data, animal findings, safety, and why no human trials exist for this off-label use.
Read clinical reviewCopper tripeptide GHK-Cu is used off-label for hair growth. Review the evidence, dosing protocols, safety data, and how GHK-Cu compares to approved hair loss treatments.
Read clinical reviewCopper tripeptide GHK-Cu is used off-label for hair growth. Review the preclinical evidence, limited human data, safety risks, and how it compares to FDA-approved options like minoxidil and finasteride.
Read clinical reviewA clinical evidence review of copper tripeptide GHK-Cu for skin regeneration, covering mechanism of action, trial data, dosing protocols, safety, and off-label status.
Read clinical reviewA clinical review of copper tripeptide GHK-Cu for skin regeneration, including off-label status, trial evidence, safety profile, and how it compares to FDA-approved alternatives.
Read clinical reviewA clinical evidence summary of copper tripeptide GHK-Cu for wound healing, including trial data, mechanism of action, dosing protocols, and off-label status.
Read clinical reviewCopper tripeptide GHK-Cu shows preclinical promise for wound healing, but remains off-label with no FDA-approved indication. Learn about dosing protocols, evidence quality, and what clinicians should know.
Read clinical reviewCopper tripeptide GHK-Cu shows preclinical promise for wound healing, but it remains off-label and unregulated as a drug. Here is the evidence, monitoring guidance, and clinical context.
Read clinical review